Bioavailability of Medical Cannabis: Flower vs Oil vs Capsule

Why Bioavailability Matters in Medical Cannabis

• Bioavailability refers to the proportion of a drug that reaches systemic circulation unchanged
• Cannabis bioavailability varies dramatically by administration route — from 6% to over 60%
• Low bioavailability means more product is needed for the same therapeutic effect — increasing cost
• Understanding bioavailability helps patients and prescribers select the most efficient preparation
• Variability in bioavailability also explains why the same dose produces different effects in different patients

Bioavailability is not a concept that receives much attention in patient-facing materials — yet it is one of the most practically important factors in medical cannabis therapy. Two patients taking the same dose of the same product may have dramatically different blood cannabinoid levels, and therefore different clinical outcomes, simply because of differences in their preferred administration route and individual metabolism.

Inhaled Cannabis: Fast Onset, Variable Absorption

• Vaporised dried flower has a bioavailability of approximately 10–35%
• Cannabinoids pass directly from the lungs into the bloodstream — onset within 2–10 minutes
• Peak plasma levels are reached within 10–30 minutes; duration of effect is 2–4 hours
• Bioavailability is highly variable due to differences in inhalation technique, puff depth, and breath hold
• Vaporisation is preferred over combustion — burning cannabis destroys cannabinoids and produces toxins

Inhaled cannabis is the fastest-acting administration route and is best suited to breakthrough pain, acute nausea, and rapidly escalating symptoms. The variability in bioavailability is a clinical limitation — standardised vaporiser devices reduce this considerably compared to smoking. For consistent therapeutic levels, however, most prescribers combine inhaled flower for acute use with an oil or capsule for baseline effect.

Sublingual Oils: Convenient and Moderately Bioavailable

• Sublingual bioavailability ranges from approximately 13–19% when held under the tongue for 60–90 seconds
• Onset is typically 15–45 minutes; duration of effect is 4–8 hours
• The sublingual route avoids significant first-pass liver metabolism compared to swallowed capsules
• If swallowed rather than absorbed sublingually, oils behave like capsules — slower and more variable
• Carrier oil (MCT, olive oil, hemp seed oil) can modestly affect cannabinoid absorption

Sublingual oils represent the most practical daily-use preparation for most medical cannabis patients. The combination of relatively predictable onset, extended duration, and ease of dose titration (by counting drops) makes oils the most commonly prescribed format in the UK. Patients should be instructed to hold the oil under the tongue — not simply swallow it — to achieve optimal sublingual absorption.

Capsules and Edibles: Consistent but Slow

• Oral bioavailability of THC is approximately 4–12% due to extensive first-pass hepatic metabolism
• Onset is slow — typically 1–3 hours — making dose titration more challenging
• Duration of effect is the longest of all routes — often 6–10 hours
• THC undergoes conversion to 11-hydroxy-THC in the liver — a more potent compound
• Capsules provide the most consistent dose-to-dose absorption when taken with a fatty meal

Oral cannabis preparations — capsules and standardised edibles — are well suited to patients requiring long-duration, consistent overnight coverage. The delayed onset is a significant drawback in acute settings, but for conditions where extended, predictable relief is the priority (chronic pain, sleep maintenance insomnia), the 6–10 hour duration is clinically valuable. Taking capsules with food containing fat significantly improves absorption.